40O Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
SAR443216 is a novel trispecific antibody targeting HER2-expressing tumors. It activates T cells for cytolysis of HER2-positive (HER2+) cancer cells by binding to CD3, CD28, and HER2. Here, we present safety, PK, and biomarker data for 9 dose levels (DLs) of SAR443216 in pts with advanced solid tumors in the IV dose-escalation cohort of a first-in-human open-label phase 1/1b trial (NCT05013554).
Authors
- Víctor Moreno (ORCID: https://orcid.org/0000-0001-6099-4236)
- Serena Masciari
- K.I. Rojas Laimito
- Dimitri Carène
- Raquel Pérez-López (ORCID: https://orcid.org/0000-0002-9176-0130)
- S. Gailhac
- Gu Mi (ORCID: https://orcid.org/0000-0001-8778-954X)
- E. Garralda
- Faı̈za Rharbaoui
- Pınar Kanlikilicer
- Barbara Buday
- W-P. Chung
- Onur Yıldırım (ORCID: https://orcid.org/0000-0002-1586-1933)
- L-Y. Bai
- Min‐Hee Ryu (ORCID: https://orcid.org/0000-0002-1033-1263)
- Giovanni Abbadessa (ORCID: https://orcid.org/0009-0007-2823-1870)
- E. Calvo
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
- L. Wang (ORCID: https://orcid.org/0009-0007-8270-4915)
- D-Y. Oh
Institutions
- Ulsan College (KR)
- The University of Texas MD Anderson Cancer Center (US)
- China Medical University (TW)
- Asan Medical Center (KR)
- Taipei Medical University Hospital (TW)
- Seoul National University Hospital (KR)
- Sanofi (France) (FR)
- University of Ulsan (KR)
- Sanofi (United States) (US)
- China Medical University Hospital (TW)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Universitario HM Sanchinarro (ES)
- National Cheng Kung University (TW)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104199
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09